Tachycardia Market Information: By type (Atrial Fibrillation, Atrial Flutter), by Treatment (Vagal Maneuvers, Medications), by Diagnosis (Imaging Tests, Electrocardiogram), and End-User (Hospitals & Clinics, Specialty Centers) Forecast Till 2030
ID: MRFR/MED/4427-HCR | 100 Pages | Published By Kinjoll Dey on March 2023
Tachycardia Market Scenario
The global tachycardia market is segmented on the basis of type, treatment, diagnosis, and end-user.
On the basis of type, the market is segmented into atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and tachy-brady syndrome.
On the basis of treatment, the market is segmented into vagal maneuvers, medications, and cardioversion. On the basis of diagnosis, the market is segmented into imaging tests, electrocardiogram, and stress test. On the basis of imaging tests, it is further sub-segmented into echocardiogram, MRI, CT scan, coronary angiogram, and chest X-ray.
On the basis of end-user, the market is segmented into ambulatory surgical centers, specialty centers, and hospitals and clinics.
Figure: Global Tachycardia Market, by Region, 2016 (%)
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis
Tachycardia Market Regional Analysis
The North American tachycardia market is a growing market in the Americas region. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing number of alcohol consumption and rising prevalence of cardiovascular rates are likely to enhance the growth of vascular closure devices. Additionally, the increasing need for minimally invasive procedures, growing healthcare expenditure, and the rising demand for technologically advanced treatments and products along with the rising government support are likely to enhance the growth of the tachycardia market in North America.
Europe is the second largest market and holds a healthy share in the global tachycardia market. The European market is expected to grow during the forecast period owing to the availability of newer and advanced treatment facilities and healthcare expenditure along with growing need for better healthcare infrastructure. Furthermore, increasing cardiovascular rates, along with rising population inclined towards sedentary lifestyle is driving the growth of the tachycardia market. According to the European Heart Network, in 2015, there were 11.3 million cardiovascular disorder cases in Europe.
Asia Pacific is expected to be the fastest growing market. The increasing prevalence of chronic diseases is the major driver for the market growth. China is the fastest growing region owing to an increasing population. The increasing awareness about health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and rise in the standard of living are driving the growth of the tachycardia market in the Asia Pacific region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and rising availability of specialty care centers.
Tachycardia Market Key Players
Some of the key players in the Tachycardia market are TZ Medical, Cardiva Medical Inc., Medtronic plc, Terumo Corporation Essential Medical, Inc., Merit Medical Systems, Inc., Abbott, Cardinal Health Inc., Inc., and Vasorum Ltd.
Research Methodology
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis
Intended Audience
- Pharmaceutical Manufacturers and Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | Significant Value |
| CAGR | 10.10% |
| Base Year | 2022 |
| Forecast Period | 2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, Diagnosis, And End-User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | TZ Medical, Cardiva Medical Inc., Medtronic plc, Terumo Corporation Essential Medical, Inc., Merit Medical Systems, Inc., Abbott, Cardinal Health Inc., Inc., and Vasorum Ltd. |
| Key Market Opportunities | Increasing approvals for vascular closure devices and government initiatives |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Tachycardia is a common type of heart disorder, which results in a faster heartbeat.
Tachycardia Market is expected to exhibit a strong 10.10% CAGR over the forecast period till 2030.
growing prevalence of cardiovascular disorders is the major driver for the Tachycardia Market.
Americas hold a dominant 48% share in the global tachycardia market.
Leading players in the Tachycardia Market include TZ Medical, Vasorum Ltd., and Medtronic, among others.
